Home » Stock Quotes » NYSEAMERICAN:ATNM

Actinium Pharmaceuticals, Inc. NYSEAMERICAN:ATNM

Today's live share price, quote history, chart & news

0.19 USD
+0.01 (4.89%)
Price open 0.19
Previous close 0.18
Market cap 31.10M
Volume 1.03M
Day high 0.19
Day low 0.18
Year high 0.60
Year low 0.17

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.

Name Actinium Pharmaceuticals, Inc.
Exchange NYSE American Stock Exchange
Sector Healthcare
Industry Biotechnology
Country United States
Full time employees 30

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.